Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5996847 | 0.90 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| Fumaric Acid SCHEMBL5996851 | 0.90 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5996512 | 0.83 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5995390 | 0.82 | SLC6A2 (0.81) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5995080 | 0.82 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5996564 | 0.81 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5995692 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5995025 | 0.78 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5993869 | 0.77 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5993154 | 0.77 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | ELI LILLY AND COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | SLC6A2, SLC18A2, SLC6A3 | SLC6A4 4/4885SLC6A2 1/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.